Figure 3

Myeloma patients harbor survivin specific CD4+CD25- T cells which respond to survivin peptide pool loaded autologous DCs. A. The survivin reactive CD4+CD25- precursor frequency for 12 consecutive myeloma patients was determined. Myeloma patients survivin reactive cells, as a % of total CD4+CD25- cells were less than that of consecutive healthy donors (p = 0.02, non-parametric t-test). B-C. Myeloma patient CD4+CD25- cells were expanded using DC:survivin as described. The survivin reactive CD4+ cell frequency (B) was significantly increased; and significant fold expansion of survivin reactive CD4+ cells was observed (C), (before expansion # of survivin reactive cells normalized to 1). Line = Mean, Box = 25%-75% CI, Whiskers = minimum and maximum, *p < 0.05 by non-parametric t-test.